The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...

Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. F ...

Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing ...

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

Meanwhile, at STAT’s Breakthrough Summit West in San Francisco, former FDA Commissioner Robert Califf criticized RFK Jr.’s ...

In this week’s edition of InnovationRx, we look at Trump's drug pricing executive order, how the cofounder of Hims became a ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...